Reading LYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LYRA free→Reading LYRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LYRA free→QuarterlyIQ Insights · LYRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement. Termination of 880 Winter Street Sublease (Waltham, Massachusetts) On April 13, 2026, Lyra Therapeutics, Inc. (the “Company”) entered into a Termination of Sublease with RVAC Medicines (US), Inc. to terminate the Company’s sublease for approximately 23,704 rentable square feet at 880 Winter Street, Waltham, Massachusetts. The sublease, dated December 21, 2023, terminated effective as of March 31, 2026, with the Company required to surrender the…
Termination of a Material Definitive Agreement. Termination of 480 Arsenal Street Lease (Watertown, Massachusetts) On March 31, 2026, Lyra Therapeutics, Inc. (the “Company”) entered into an Agreement for Termination of Lease and Voluntary Surrender of Premises with ARE-480 Arsenal Street, LLC to terminate the Company’s lease for approximately 22,343 rentable square feet at 480 Arsenal Way, Suites 200 and 200A, Watertown, Massachusetts. The lease, as amended, was originally scheduled to expire…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 13, 2026, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Letter”) from the Nasdaq Hearings Advisor at The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has withdrawn its appeal of the delisting determination issued by Nasdaq’s Listings Qualifications Staff on February 2, 2026. The Letter further confirms that as a result of the withdrawal of the Compa…
Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement. On February 23, 2026, Lyra Therapeutics, Inc. (the “Company”) received a notice of default from RVAC Medicines (US), Inc. (“RVAC”) under the sublease agreement dated December 21, 2023 (the “Sublease”) between RVAC, as sublessor, and the Company, as sublessee, for office space located at 880 Winter Street, Suite 1002, Waltham, MA 02451 (the “Premises”). Pursuant to the notice of…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 2, 2026, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Staff Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has determined to delist the Company’s common stock from The Nasdaq Stock Market. The Company has requested a hearing before a Nasdaq Hearings Panel to appeal Nasd…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 9, 2026, in connection with the Plan described in Item 2.05, the employment of Dr. Maria Palasis, the Company’s Chief Executive Officer, President and Chairman of the Board, and of Mr. Jason Cavalier, the Company’s Chief Financial Officer and Treasurer, was terminated. The Company anticipates entering into a separation and release agreem…
Other Events. As part of its ongoing review of strategic alternatives initially announced in May 2024, the Company’s Board of Directors has concluded that it is in the best interest of stockholders to cease the Company’s product development operations and suspend further development of LYR-210. The Company’s recent clinical update in June 2025 reported positive data from the ENLIGHTEN 2 Phase 3 trial of LYR-210 achieving statistically significant results for primary and key secondary endpoint…
Costs Associated with Exit or Disposal Activities. On January 9, 2026, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) approved a plan to suspend further development of LYR-210, the Company’s lead product candidate for the treatment of chronic rhinosinusitis, and to implement a cost reduction plan that includes a workforce reduction impacting substantially all of the Company’s remaining employees, effective January 12, 2026, and other cost-saving actions to preserve capital…
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 20, 2025, Lyra Therapeutics, Inc. (the “Company”) received a letter (the “Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”), did not satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the…
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 1, 2025, Lyra Therapeutics, Inc. (the “Company”) and Harlan W. Waksal, M.D., the Company’s Executive Chairman, agreed to terminate his employment effective immediately. Subject to Dr. Waksal entering into a separation agreement with the Company containing a release of claims, he will be entitled to receive the severance payments and benef…
in its entirety. Based in part upon the representations of the Purchasers in the Purchase Agreement, the offering and sale of the Private Warrants will be exempt from registration under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act. The sales of the Private Warrants and the shares of Common Stock issuable upon exercise of the Private Warrants by the Company in the Private Placement will not be registered under the Securities Act or…
Entry into a Material Definitive Agreement. On June 26, 2025, Lyra Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Purchasers”). The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of: (i) 273,012 shares (the “Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”), (ii) pre-funded warrants (the…
Other Events. On June 27, 2025, the Company issued a press release announcing the pricing of the Registered Direct Offering and Private Placement described above in
Other Events. As disclosed above, at the Meeting, the stockholders of the Company approved a reverse stock split of all outstanding shares of the Common Stock, at a ratio ranging from any whole number between 1-for-10 and 1-for-50, with the exact ratio as determined by the Board in its discretion, subject to the Board’s authority to abandon such amendments. On May 14, 2025, the Board approved a reverse stock split of the Common Stock at a final ratio of 1-for-50 (the “Reverse Stock Split”) an…
of this Current Report on Form 8-K shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on May 6, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: May 6, 2025 By: /s/ Jason Cavalier Jason…
of this Current Report on Form 8-K shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on March 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lyra Therapeutics, Inc. Date: March 13, 2025 By: /s/ Jason Cavalier J…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.